Pharmaceutical

Genentech signs nanoparticle deal worth up to $644m with GenEdit

Genentech will utilise GenEdit’s non-viral polymer nanoparticles for gene therapy delivery in autoimmune diseases.

Jan 23, 2024 - 18:00
Genentech signs nanoparticle deal worth up to $644m with GenEdit
Genentech will utilise GenEdit’s non-viral polymer nanoparticles for gene therapy delivery in autoimmune diseases.
Read the original article

Tags:

Previous Article

Newly launched Calluna raises $81m to advance monoclonal antibody pipeline

Next Article

Sanofi signs agreement to acquire Inhibrx for $1.7bn

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

ARS Pharmaceuticals’ anaphylaxis nasal spray gains FDA approval

ARS Pharmaceuticals’ anaphylaxis nasal spray gains FDA ...

Aug 13, 2024

ABBV-101 by AbbVie for Relapsed Chronic Lymphocytic Leu...

Jul 7, 2023

Who’s acquiring who? Virtual care M&A activity in the pharmaceutical industry increased by 100% in Q1 2023

Who’s acquiring who? Virtual care M&A activity in the p...

May 28, 2023